Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 7/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3420198 | 0.93 | EGLN3 (0.53) | EGLN3EGLN1EGLN2GAAHTT | |
| SCHEMBL3422566 | 0.81 | EGLN3 (0.54) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL19267291 | 0.78 | EGLN3 (0.43) | EGLN3EGLN1EGLN2 | |
| SCHEMBL3421421 | 0.76 | EGLN3 (0.65) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL3419496 | 0.76 | EGLN3 (0.55) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL3419613 | 0.75 | EGLN3 (0.61) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL3419035 | 0.74 | EGLN3 (0.54) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL4787246 | 0.73 | EGLN3 (0.74) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL3424032 | 0.73 | EGLN3 (0.54) | EGLN3EGLN1EGLN2HTTCYSLTR2 | |
| SCHEMBL3420778 | 0.73 | EGLN3 (0.58) | EGLN3EGLN1EGLN2CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885PPARG 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.